BioCentury
ARTICLE | Financial News

Insiders back Lysosomal in $20M A round

February 4, 2015 2:55 AM UTC

Lysosomal Therapeutics Inc. (Cambridge, Mass.) raised $20 million in a series A round from existing investors including Atlas Venture; Hatteras Venture Partners; Lilly Ventures; Sanofi-Genzyme BioVentures; Roche Venture Fund; Partners Innovation Fund; Orion Equity Partners; and company co-founders Henri Termeer and Bob Carpenter.

The company expects to begin clinical testing in early 2017 of a glucocerebrosidase (GBA; GCase) lysosomal enzyme activator candidate to treat Parkinson's disease (PD). The biotech has a license from NIH to allosteric modulators that increase GCase activity in the lysosome (see BioCentury, May 26, 2014). ...